Pharvaris Future Growth
Future criteria checks 0/6
Pharvaris is forecast to grow earnings and revenue by 10.1% and 78.4% per annum respectively. EPS is expected to grow by 15.4% per annum. Return on equity is forecast to be -93.9% in 3 years.
Key information
10.1%
Earnings growth rate
15.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 78.4% |
| Future return on equity | -93.9% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -172 | -190 | -168 | 6 |
| 12/31/2025 | N/A | -161 | -165 | -142 | 5 |
| 12/31/2024 | N/A | -138 | -133 | -116 | 5 |
| 9/30/2024 | N/A | -132 | -109 | -109 | N/A |
| 6/30/2024 | N/A | -114 | -99 | -99 | N/A |
| 3/31/2024 | N/A | -106 | -92 | -92 | N/A |
| 12/31/2023 | N/A | -101 | -93 | -93 | N/A |
| 9/30/2023 | N/A | -107 | -90 | -90 | N/A |
| 6/30/2023 | N/A | -92 | -81 | -81 | N/A |
| 3/31/2023 | N/A | -83 | -75 | -74 | N/A |
| 12/31/2022 | N/A | -76 | -67 | -67 | N/A |
| 9/30/2022 | N/A | -49 | -59 | -59 | N/A |
| 6/30/2022 | N/A | -50 | -54 | -54 | N/A |
| 3/31/2022 | N/A | -53 | -52 | -52 | N/A |
| 12/31/2021 | N/A | -43 | -45 | -45 | N/A |
| 9/30/2021 | N/A | -41 | -41 | -41 | N/A |
| 6/30/2021 | N/A | -38 | -38 | -38 | N/A |
| 3/31/2021 | N/A | -29 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -26 | -22 | -21 | N/A |
| 9/30/2020 | N/A | -19 | -16 | -16 | N/A |
| 12/31/2019 | N/A | -8 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9EN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9EN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9EN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9EN is forecast to have no revenue next year.
High Growth Revenue: 9EN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9EN is forecast to be unprofitable in 3 years.